New drug may cause fewer side effects than standard prostate cancer treatment
NCT ID NCT05526248
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study looked at two drugs, darolutamide and enzalutamide, in men with prostate cancer that had come back after initial treatment but had not yet been treated with hormone therapy. The goal was to see how each drug affects testosterone levels and side effects like breast tenderness. 28 men took part, first all receiving darolutamide, then some switched to enzalutamide for comparison. The study aimed to find out if darolutamide causes fewer hormone-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center - Oncology
Boston, Massachusetts, 02215, United States
-
Central Ohio Urology Group - Gahanna
Gahanna, Ohio, 43230, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114-2696, United States
-
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York, 10065, United States
-
Unio Specialty Care - Urology - Sherman Oaks
Sherman Oaks, California, 91411, United States
Conditions
Explore the condition pages connected to this study.